Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene

Hypertension Research - Clinical and Experimental

Volumn 19, Issue 3, 1996, Pages 151-159

  Wegner, Max ^a   Hirth Dietrich, Claudia ^a   Knorr, Andreas ^a   Dressel, Jürgen ^b   Ganten, Detlev ^c   Stasch, Johannes Peter ^a  

^a BAYER AG   (Germany)

^b Dep of Chemistry and Inst of   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Alatriopril; ANP; Ecadotril; Hypertension; TGR(mRen2)27

Indexed keywords

ANGIOTENSIN I; ATRIAL NATRIURETIC FACTOR; CAPTOPRIL; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; FASIDOTRIL; FASIDOTRILAT; RENIN; SINORPHAN; THIORPHAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DIURESIS; DOSE RESPONSE; DRUG EFFICACY; GENE; HEART FAILURE; HEART RATE; HEMODYNAMICS; HYPERTENSION; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; RAT; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; TRANSGENIC ANIMAL;

EID: 0030002716     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.19.151     Document Type: Article

References (45)

1. Ruskoaho H: Atrial natriuretic peptide: synthesis, release, and metabolism. Pharacol Rev 1992; 44: 479-602.
2. Olins GM, Spear KL, Siegel MR, Zurcher-Neely HA: Inactivation of atrial natriuretic factor by the renal brush border. Biochim Biophys Acta 1987; 901: 97-100.
3. Olins GM, Krieter PA, Trapani AJ, Spear KL, Bovy BR: Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo. Mol Cell Endocrinol 1989; 61: 201-208.
4. Sybertz EJ, Chiu PJS, Vemulapalli S, et al: SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial nautriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J Pharmacol Exp Ther 1989; 250: 624-631.
5. Koepke JP, Tylor LD, Mehta PP, et al: Atriopeptin regulation and renal function in conscious spontaneously hypertensive rats. Am J Hypertens 1990; 3: 622-627.
6. Vemulapalli S, Chiu PJS, Brown A, Griscti K, Sybertz EJ: The blood pressure and renal responses to SCH 34826, a neutral metalloendopeptidase inhibitor, and C-ANF(4-23) in DOCA-salt hypertensive rats. Life Sci 1991; 49: 383-391.
7. Seymour AA, Norman JA, Asaad MM, et al: Possible regulation of atrial natriuretic factor by neutral endopeptidase 24.11 and clearance receptors. J Pharmacol Exp Ther 1991; 256: 1002-1009.
8. Danilewiez JC, Barclay PL, Barnish IT, et al: UK-69,578, a novel inhibitor of E.C. 3.4.24.11 which increases endogenous ANF levels and its natriuretic and diuretic response. Biochem Biophys Res Commun 1989; 164: 58-65.
9. Pham I, El Amrani AIK, Fournie-Zaluski MC, Corvol P, Roques BP, Michel JB: Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats. J Cardiovasc Pharmacol 1992; 20: 847-857.
10. Schwartz JC, Gros C, Lecomte JM, Bralet J: Enkephalinase (EC 3.4.24.11) inhibitors. Protection of endogenous ANF against inactivation and potential the rapeutic applications. Life Sci 1990; 47: 1279-1297.
11. Seymour AA, Swerdel JN, Fennell SA, Druckman P, Neubeck R, Delaney NG: Potentiation of the depressor responses to atrial natriuretic peptides in conscious SHR by an inhibitor of neutral endopeptidase. J Cardiovasc Pharmacol 1989; 14: 194-204.
12. Wilkins MR, Settle SL, Stockmann PT, Needleman P: Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. Proc Natl Acad Sci USA 1990; 87: 6465-6469.
13. Seymour AA, Norman JA, Assad MM, et al: Renal and depressor effects of SQ 29,072, a neutral endopeptidase inhibitor, in conscious hypertensive rats. J Cardiovasc Pharmacol 1990; 16: 163-172.
14. Gavras H, Gavras I: Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens 1991; 1: 385-392.
15. Laragh J: New angiotensin converting enzyme inhibitors. Am J Hypertens 1990; 3: 257S-265S.
16. Waeber B, Nussberger J, Brunner H: Pathology, diagnosis and management, in Laragh JH, Brenner BM (eds): Hypertension. New York, Raven Press, 1990, 2, pp2209-2232.
17. Gros C, Noel N, Souque A, et al: Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopil. Proc Natl Acad Sci USA 1991; 88: 4210-4214.
18. Fournie-Zaluski MC, Coric P, Turcaud S, et al: New dual inhibitors of neutral endopeptidase and angiotension-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension. J Med Chem 1994; 37: 1070-1083.
19. Fournie-Zaluski MC, Gonzalez W, Turcaud S, Pham I, Roques BP, Michel JB: Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc Natl Acad Sci 1994; 91: 4072-4076.
20. Pham I, Gonzales W, El Amrani AIK, et al: Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther 1993; 265: 1339-1347.
21. Flynn GA, Beight DW, Mehidi S, et al: Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J Med Chem 1993; 36: 2420-2423.
22. Stanton JL, Sperbeck DM, Trapani AJ, et al: Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors. J Med Chem 1993; 36: 3829-3833.
23. French JF, Flynn GA, Giroux EL, et al: Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J Pharmacol Exp Ther 1994; 268: 180-186.
24. Bralet J, Marie C, Mossiat C, Lecomte JM, Gros C, Schwartz JC: Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril. J Pharmacol Exp Ther 1994; 270: 8-14.
25. Richard V, Lecomte JM, Thuillez C: Effets hemodynamiques systemiques et regionaux d'un nouvel inhibiteur mixte de l'enzyme de conversion de l'angiotensine et de l'endopeptidase neutre, l'alatriopril, chez le chien. Arch Mal Coeur 1993; 86: 1275-1279.
26. Vera WG, Fournie-Zaluski MC, Pham I, Laboulandine I, Roques BP, Michel JB: Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J Pharmacol Exp Ther 1995; 272: 341-351.
27. Bachmann S, Peters J, Engler E, Ganten D, Mullins J: Transgenic rats carrying the mouse renin gene: morphological characterization of a low-renin hypertension model. Kidney Int 1992; 41: 24-36.
28. Stasch JP, Hirth-Dietrich C, Ganten D, Wegner M: Cardiorenal consequences of neutral endopeptidase inhibition in transgenic rats with an extra renin gene. Am J Hypertens 1996; 9 (in press).
29. Hirth-Dietrich C, Stasch JP, Ganten D, Luft FC: Renal effects of captopril and nitrendipine in transgenic rats with an extra renin gene. Hypertension 1994; 23: 626-631.
30. Yandle T, Richards M, Smith M, Charles C, Livesey J, Espiner E: Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin Chem 1992; 38: 1785-1791.
31. Hirata Y, Suzuki E, Hayakawa H, et al: Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats. J Cardiovasc Pharmacol 1994; 23: 283-290.
32. Stasch JP, Knorr A, Wegner M, Hirth-Dietrich C: Prolonged inhibition of neutral endopeptidase 24.11 by sinorphan in SHR-SP. Hypertens Res 1995; 18: 1128-1134.
33. Crozier IG, Nicholls MG, Ikram H, Espiner EA, Yandle TG: Atrial natriuretic peptide levels in congestive heart failure in man before and during converting enzyme inhibition. Clin Exp Pharmacol Physiol 1989; 16: 417-424.
34. Michel JB, Lattion AL, Salzmann JL, et al: Hormonal and cardiac effect of converting enzyme inhibition in rat myocardial infarction. Circ Res 1988; 62: 641-650.
35. Seymour AA, Swerdel JN, Abboa-Offei B: Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 1991; 17 456-465.
36. Pham I, Levy B, Fournie-Zaluski, Poitevin P, Roques BP, Michel JB: Acute hemodynamic effects of combined inhibition of neutral endopeptidase and angiotensin converting enzyme in spontaneously hypertensive rats. Fundam Clin Pharmacol 1995; 9: 153-160.
37. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, Beaumont A: Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993; 45: 87-146.
38. Roques PB: Zinc metallopeptidases active site structure and design of selective and mixed inhibitors: new approaches in the search for analgesics and antihypertensives. Biochem Soc Trans 1993; 21: 678-685.
39. Wegner M, Kazda S, Hirth-Dietrich C, Dressel J, Voges KP, Stasch JP: Interaction of an endopeptidase inhibitor and an ANP-C receptor ligand in anaesthetized dogs. Clin Exp Hypertens 1995; 17: 861-876.
40. Wegner M, Stasch JP, Hirth-Dietrich C: Role of neutral endoeptidase 24.11 in AV fistular rat model of heart failure. Cardiovasc Res 1996; 31: 891-898.
41. Dussaule JC, Michel C, Peraldi MN: Inhibition of neutral endopeptidase stimulates renal sodium excretion in patients with chronic heart failure. Clin Sci 1993; 84: 31-39.
42. Smits GJ, McGraw DE, Trapani AJ: Interaction of ANP and brady kinin during endopeptidase 24.11. inhibition: renal effects. Am J Physiol 1990; 258: F1417-F1424.
43. Sybertz EJ, Chiu PJS, Vemulapalli S, Watkins R, Haslanger M: Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826: an orally active neutral metalloendopeptidase inhibitor. Hypertension 1990; 15: 152-161.
44. Hirata Y, Matsuoka H, Hayakawa H, et al: Role of endogenous atrial natriuretic peptide in regulating sodium excretion in spontaneously hypertensive rats: effects of neutral endopeptidase inhibition. Hypertension 1990; 17: 1025-1032.
45. Kahn JC, Patey M, Dubois-Rande JL, et al: Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 1990; 335: 118-119.